JP2017535564A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017535564A5 JP2017535564A5 JP2017527299A JP2017527299A JP2017535564A5 JP 2017535564 A5 JP2017535564 A5 JP 2017535564A5 JP 2017527299 A JP2017527299 A JP 2017527299A JP 2017527299 A JP2017527299 A JP 2017527299A JP 2017535564 A5 JP2017535564 A5 JP 2017535564A5
- Authority
- JP
- Japan
- Prior art keywords
- crystalline form
- further characterized
- compound
- ray powder
- powder diffraction
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229940126062 Compound A Drugs 0.000 claims 8
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 claims 8
- 238000000634 powder X-ray diffraction Methods 0.000 claims 6
- 230000003796 beauty Effects 0.000 claims 4
- 239000013078 crystal Substances 0.000 claims 3
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical group OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 claims 2
- IQAIPUWCYPGRQL-UHFFFAOYSA-N 2-hydroxyacetic acid;hydrate Chemical group O.OCC(O)=O IQAIPUWCYPGRQL-UHFFFAOYSA-N 0.000 claims 2
- ODHCTXKNWHHXJC-VKHMYHEASA-N 5-oxo-L-proline Chemical group OC(=O)[C@@H]1CCC(=O)N1 ODHCTXKNWHHXJC-VKHMYHEASA-N 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- CTLOSZHDGZLOQE-UHFFFAOYSA-N 14-methoxy-9-[(4-methylpiperazin-1-yl)methyl]-9,19-diazapentacyclo[10.7.0.02,6.07,11.013,18]nonadeca-1(12),2(6),7(11),13(18),14,16-hexaene-8,10-dione Chemical compound O=C1C2=C3C=4C(OC)=CC=CC=4NC3=C3CCCC3=C2C(=O)N1CN1CCN(C)CC1 CTLOSZHDGZLOQE-UHFFFAOYSA-N 0.000 claims 1
- -1 4-methyl-1-piperazinyl Chemical group 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- JJRIKULPYPZZHU-UHFFFAOYSA-N carbazole-1,3-dione Chemical compound C1=CC=C2C3=CC(=O)CC(=O)C3=NC2=C1 JJRIKULPYPZZHU-UHFFFAOYSA-N 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462084652P | 2014-11-26 | 2014-11-26 | |
| US62/084,652 | 2014-11-26 | ||
| PCT/US2015/062572 WO2016086080A1 (en) | 2014-11-26 | 2015-11-25 | Crystalline forms of parp inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2017535564A JP2017535564A (ja) | 2017-11-30 |
| JP2017535564A5 true JP2017535564A5 (OSRAM) | 2018-12-27 |
Family
ID=54849709
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017527299A Pending JP2017535564A (ja) | 2014-11-26 | 2015-11-25 | Ｐａｒｐ阻害剤の結晶形態 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US10150772B2 (OSRAM) |
| EP (1) | EP3224259A1 (OSRAM) |
| JP (1) | JP2017535564A (OSRAM) |
| KR (1) | KR20170088894A (OSRAM) |
| CN (1) | CN107207511A (OSRAM) |
| AU (1) | AU2015353549A1 (OSRAM) |
| BR (1) | BR112017010588A2 (OSRAM) |
| CA (1) | CA2967828A1 (OSRAM) |
| HK (1) | HK1244006A1 (OSRAM) |
| IL (1) | IL252162A0 (OSRAM) |
| MX (1) | MX2017006679A (OSRAM) |
| RU (1) | RU2017120655A (OSRAM) |
| WO (1) | WO2016086080A1 (OSRAM) |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060276497A1 (en) * | 2000-05-09 | 2006-12-07 | Cephalon, Inc. | Novel multicyclic compounds and the use thereof |
| US7122679B2 (en) | 2000-05-09 | 2006-10-17 | Cephalon, Inc. | Multicyclic compounds and the use thereof |
| WO2008063644A1 (en) * | 2006-11-20 | 2008-05-29 | Cephalon, Inc. | Method of radio-sensitizing tumors using a radio-sensitizing agent |
| DK2470540T3 (en) * | 2009-08-26 | 2016-08-01 | Cephalon Inc | Novel forms a multi-cyclic compound |
-
2015
- 2015-11-25 BR BR112017010588-8A patent/BR112017010588A2/pt not_active Application Discontinuation
- 2015-11-25 JP JP2017527299A patent/JP2017535564A/ja active Pending
- 2015-11-25 CN CN201580063386.3A patent/CN107207511A/zh active Pending
- 2015-11-25 RU RU2017120655A patent/RU2017120655A/ru not_active Application Discontinuation
- 2015-11-25 HK HK18103530.1A patent/HK1244006A1/zh unknown
- 2015-11-25 AU AU2015353549A patent/AU2015353549A1/en not_active Abandoned
- 2015-11-25 US US15/529,883 patent/US10150772B2/en not_active Expired - Fee Related
- 2015-11-25 CA CA2967828A patent/CA2967828A1/en not_active Abandoned
- 2015-11-25 KR KR1020177016523A patent/KR20170088894A/ko not_active Withdrawn
- 2015-11-25 EP EP15808507.6A patent/EP3224259A1/en not_active Withdrawn
- 2015-11-25 WO PCT/US2015/062572 patent/WO2016086080A1/en not_active Ceased
- 2015-11-25 MX MX2017006679A patent/MX2017006679A/es unknown
-
2017
- 2017-05-08 IL IL252162A patent/IL252162A0/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018024682A5 (OSRAM) | ||
| WO2014199397A3 (en) | Process for the preparation of liraglutide | |
| WO2012044727A3 (en) | Manufacturing process for pyrimidine derivatives | |
| JP2013237682A5 (OSRAM) | ||
| JP2013032389A5 (OSRAM) | ||
| JP2011518833A5 (OSRAM) | ||
| TN2013000434A1 (en) | Novel imidazole derivatives useful for the treatment of arthritis | |
| JP2013525444A5 (OSRAM) | ||
| ES2613716T3 (es) | Formas cristalinas de un derivado de purina | |
| JP2015520140A5 (OSRAM) | ||
| JP2014527042A5 (OSRAM) | ||
| PH12013500301A1 (en) | Oxadiazole inhibitors of leukotriene production | |
| JP2015522037A5 (OSRAM) | ||
| JP2013532130A5 (OSRAM) | ||
| WO2014153203A3 (en) | Alkyl-amine harmine derivatives for promoting bone growth | |
| JP2014530818A5 (OSRAM) | ||
| HK1210771A1 (zh) | 氮杂吲哚衍生物 | |
| JP2016510768A5 (OSRAM) | ||
| JP2015516425A5 (OSRAM) | ||
| JP2016532632A5 (OSRAM) | ||
| EA201300647A1 (ru) | Оптимизированный синтез чистых неполиморфных кристаллических жёлчных кислот с заданным размером частиц | |
| WO2014164648A4 (en) | Solid state forms of a quinazoline derivative and its use as a braf inhibitor | |
| CA2922375C (en) | Alpha-tea salt forms: compositions and uses for treating disease | |
| IN2013DN02555A (OSRAM) | ||
| JP2016510767A5 (OSRAM) |